Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers

Abstract

Among postmenopausal women with a BRCA1 mutation, HT use was not associated with increased risk of breast cancer; indeed, in this population, it was associated with a decreased risk.